Photocure completes Visonac study enrolment
Photocure has completed patient enrolment according to schedule in its Phase IIb study using Visonac, a topical acne treatment.
The Phase IIb trial is a randomised, double-blind, placebo-controlled study in patients with moderate-to-severe acne vulgaris. It will measure safety and efficacy in patients aged 12 to 35 years, who will receive four treatments over a six-week period. The cream is applied to the acne area, and after a short incubation time, the skin is illuminated with red light. A total of 15 office-based dermatology practices and hospitals in the US have recruited 150 patients to the study. The results are anticipated in the third quarter of 2012 and will support the design of the pivotal Phase III studies in the US and Europe.